Verici Dx plc

Company Profile

Company website
Health Care/Medical Equipment and Services (Medical Services)

Verici Dx is a developer of a complementary suite of leading-edge tests forming a kidney transplant platform for personalised patient and organ response risk to assist clinicians in medical management for improved patient outcomes.  The underlying technology is based upon artificial intelligence assisted transcriptomic analysis to provide RNA signatures focused upon the immune response and other biological pathway signals critical for transplant prognosis of risk of injury, rejection and graft failure from pre-transplant to late stage.  The Company also has a mission to accelerate the pace of innovation by research using the fully characterised data from the underlying technology and collaboration with medical device, biopharmaceutical and data science partners.

The foundational research was driven by a deep understanding of cell-mediated immunity and is enabled by access to expertly curated collaborative studies in highly informative cohorts in kidney transplant.

Investor Access

07 Sep
Event information
Management will hold a presentation for Investors through the digital platform, Investor Meet Company, on Wednesday 7th September 2022 at 3pm relating to the interim results for the six months ended 30 June 2022.  Investors can sign up to Investor Meet Company for free, by clicking here
Wednesday 7th September 2022 at 3pm
Financial Calendar
 Event  Date
Year End TBC
Half  Year End TBC
Preliminary Results* TBC
Interim Results* TBC

* Months based on previous announcements of this kind